SEARCH

SEARCH BY CITATION

References

  • 1
    Jaffe ES, Harris NL, Stein H et al. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008; 112: 43844399.
  • 2
    Campo E, Swerdlow SH, Harris NL et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 50195032.
  • 3
    Lewis JD. Risk of lymphoma in patients with inflammatory bowel disease. Gastroenterol. Hepatol. (N. Y.) 2012; 8: 4547.
  • 4
    Paltiel O, Schmit T, Adler B et al. The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study. Cancer 2000; 88: 23572366.
  • 5
    Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 15141516.
  • 6
    Wilkinson AH, Smith JL, Hunsicker LG et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47: 293296.
  • 7
    Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 2004; 4: 222230.
  • 8
    Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol. Biomarkers. Prev. 2006; 15: 20692077.
  • 9
    Jones M, Symmons D, Finn J et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br. J. Rheumatol. 1996; 35: 738745.
  • 10
    Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54: 692701.
  • 11
    Lewis JD, Bilker WB, Brensinger C et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121: 10801087.
  • 12
    Ekbom A, Helmick C, Zack M et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991; 67: 20152019.
  • 13
    Karlen P, Lofberg R, Brostrom O et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am. J. Gastroenterol. 1999; 94: 10471052.
  • 14
    Persson PG, Karlen P, Bernell O et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994; 107: 16751679.
  • 15
    Loftus EV Jr, Tremaine WJ, Habermann TM et al. Risk of lymphoma in inflammatory bowel disease. Am. J. Gastroenterol. 2000; 95: 23082312.
    Direct Link:
  • 16
    Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91: 854862.
  • 17
    Palli D, Trallori G, Bagnoli S et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000; 119: 647653.
  • 18
    Jess T, Winther KV, Munkholm P et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment. Pharmacol. Ther. 2004; 19: 287293.
  • 19
    Winther KV, Jess T, Langholz E et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin. Gastroenterol. Hepatol. 2004; 2: 10881095.
  • 20
    Askling J, Brandt L, Lapidus A et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005; 54: 617622.
  • 21
    Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 16171625.
  • 22
    Vos AC, Bakkal N, Minnee RC et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm. Bowel Dis. 2011; 17: 18371845.
  • 23
    Kandiel A, Fraser AG, Korelitz BI et al. Increased risk of lymphomaamong inflammatory bowel disease patients treated with azathioprine and 6 mercaptopurine. Gut 2005; 54: 11211125.
  • 24
    Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 2009; 7: 874881.
  • 25
    Fraser AG, Orchard TR, Robinson EM et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment. Pharmacol. Ther. 2002; 16: 12251232.
  • 26
    Farrell RJ, Ang Y, Kileen P et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47: 514519.
  • 27
    Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am. J. Gastroenterol. 2010; 105: 16041609.
  • 28
    Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am. J. Med. 1985; 78: 4449.
  • 29
    Connell WR, Kamm MA, Dickson M et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 12491252.
  • 30
    Korelitz BI, Mirsky FJ, Fleisher MR et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am. J. Gastroenterol. 1999; 94: 32483253.
    Direct Link:
  • 31
    Sultan K, Korelitz BI, Present D et al. Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease. Inflamm. Bowel Dis. 2012; 18: 18551858.
  • 32
    Siegel C, Hur C, Korzenik JR et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin. Gastroenterol. Hepatol. 2006; 4: 10171024.
  • 33
    Swerdlow SH. T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am. J. Clin. Pathol. 2007; 127: 887895.
  • 34
    Jagadeesh D, Woda BA, Draper J et al. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr. Treat. Options Oncol. 2012; 13: 122136.
  • 35
    Swerdlow SH, Harris NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: International Agency for Research on Cancer, 2008.
  • 36
    Mariette X, Cazals-Hatem D, Warszawki J et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99: 39093915.
  • 37
    Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18 572 patients. Arthritis Rheum. 2004; 50: 17401751.
  • 38
    Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 849853.
  • 39
    Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 1931.
  • 40
    Lichtenstein GR, Cohen RD, Feagan BG. Safety of infliximab and other Crohn's disease therapies—Treat Registry Data with nearly 15 000 patient-years of follow-up. Gastroenterology 2006; 130: A71.
  • 41
    Herrinton LJ, Liu L, Weng X et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am. J. Gastroenterol. 2011; 106: 21462153.
  • 42
    Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 2008; 6: 644653.
  • 43
    Sokol H, Beaugerie L, Maynadié M et al. for the CESAME Study Group. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2012; 18: 20632071.
  • 44
    Dayharsh GA, Loftus EV Jr, Sandborn WJ et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122: 7277.
  • 45
    Reijasse D, Le Pendeven C, Cosnes J et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm. Bowel Dis. 2004; 10: 8590.
  • 46
    Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev. Clin. Immunol. 2010; 6: 137154.
  • 47
    Henter JI, Elinder G, Soder O et al. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr. Scand. 1991; 80: 428435.
  • 48
    Babu TG, Boctor D, Davey A et al. Cytomegalovirus associated hemophagocytic syndrome in a child with Crohn disease receiving azathioprine. J. Pediatr. Gastroenterol. Nutr. 2004; 39: 418421.
  • 49
    Biank Sheth MK, Talano J et al. Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis. J. Pediatr. 2011; 159: 808812.
  • 50
    Chauveau E, Terrier F, Casassus-Buihle D et al. Macrophage activation syndrome after treatment with infliximab for fistulated Crohn disease. Presse Med. 2005; 34: 583584.
  • 51
    Côté-Daigneault J, Bernard EJ. Hepatosplenic lymphoma presenting initially as hemophagocytic syndrome in a 21-year-old man with Crohn's disease: a case report and literature review. Can. J. Gastroenterol. 2011; 25: 417418.
  • 52
    Dhote R, Simon J, Papo T et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003; 49: 633639.
  • 53
    Francolla KA, Altman A, Sylvester FA. Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. J. Pediatr. Gastroenterol. Nutr. 2008; 47: 193195.
  • 54
    Jaing TH, Chiu CH, Lo WC et al. Epstein-Barr virus associated hemophagocytic syndrome masquerading as lymphoma: a case report. J. Microbiol. Immunol. Infect. 2001; 34: 147149.
  • 55
    Janka G, Imashuku S, Elinder G et al. Infection- and malignancy-associated hemophagocytic syndromes: secondary hemophagocytic lymphohistiocytosis. Hematol. Oncol. Clin. North Am. 1998; 12: 435444.
  • 56
    Kanaji S, Okuma K, Tokumitsu Y et al. Hemophagocytic syndrome associated with fulminant ulcerative colitis and presumed acute pancreatitis. Am. J. Gastroenterol. 1998; 93: 19561959.
  • 57
    Koketsu S, Watanabe T, Hori N et al. Hemophagocytic syndrome caused by fulminant ulcerative colitis and cytomegalovirus infection: report of a case. Dis. Colon Rectum 2004; 47: 12501253, discussion 3–5.
  • 58
    Kohara MM, Blum RN. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody. Clin. Infect. Dis. 2006; 42: 733734.
  • 59
    N'Guyen Y, Baumard S, Salmon JH et al. Cytomegalovirus associated hemophagocytic lymphohistiocytosis in patients suffering from Crohn's disease treated by azathioprine: a series of four cases. Inflamm. Bowel Dis. 2011; 17: E116118.
  • 60
    Presti MA, Costantino G, Della Torre A et al. Severe CMV-related pneumonia complicated by the hemophagocytic lymphohistiocytic (HLH) syndrome in quiescent Crohn's colitis: harmful cure? Inflamm. Bowel Dis. 2011; 17: E145146.
  • 61
    Salado CT, Gallego AG, Carnerero EL et al. Hemophagocytic lymphohistiocytosis in Crohn's disease associated with primary infection by Epstein-Barr virus. Inflamm. Bowel Dis. 2011; 17: E143144.
  • 62
    van Langenberg DR, Morrison G, Foley A et al. Cytomegalovirus disease, haemophagocytic syndrome, immunosuppression in patients with IBD: “a cocktail best avoided, not stirred”. J. Crohns Colitis 2011; 5: 469472.
  • 63
    Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann. Med. 2006; 38: 2031.
  • 64
    Imashuku S. Clinical features and treatment strategies of Epstein- Barr virus-associated hemophagocytic lymphohistiocytosis. Crit. Rev. Oncol. Hematol 2002; 44: 259272.
  • 65
    Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr. Opin. Hematol. 2008; 15: 576585.
  • 66
    van Laar JA, Buysse CM, Vossen AC et al. Epstein-Barr viral load assessment in immunocompetent patients with fulminant infectious mononucleosis. Arch. Intern. Med. 2002; 162: 837839.
  • 67
    Henter JI, Horne A, Arico M et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 2007; 48: 124131.
  • 68
    Kotlyar DS, Osterman MT, Diamond RH et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2011; 9: 3641.
  • 69
    Ferreri AJ, Govi S, Pileri SA. Hepatosplenic gamma-delta T-cell lymphoma. Crit. Rev. Oncol. Hematol 2012; 83: 283292.
  • 70
    Vega F, Medeiros LJ, Gaulard P. Hepatosplenic and other gammadelta T-cell lymphomas. Am. J. Clin. Pathol. 2007; 127: 869880.
  • 71
    Jaffe ES. Pathobiology of peripheral T-cell lymphomas. Hematology Am. Soc. Hematol. Educ. Program 2006; 1: 317322.
  • 72
    Belhadj K, Reyes F, Farcet JP et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 42614269.
  • 73
    Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14: 991997.
  • 74
    Parakkal D, Sifuentes H, Semer R et al. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. Eur. J. Gastroenterol. Hepatol. 2011; 23: 11501156.
  • 75
    Konuma T, Ooi J, Takahashi S et al. Allogeneic stem cell transplantation for hepatosplenic gammadelta T-cell lymphoma. Leuk. Lymphoma 2007; 48: 630632.